Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
159 studies found for:    "Gout"
Show Display Options
RSS Create an RSS feed from your search for:
"Gout"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Lesinurad and Febuxostat Combination Extension Study in Gout
Condition: Gout
Intervention: Drug: lesinurad
2 Completed
Has Results
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Condition: Gout
Interventions: Drug: lesinurad;   Drug: Placebo
3 Withdrawn Allopurinol in Acute Gout
Condition: Gout
Intervention: Drug: allopurinol
4 Completed
Has Results
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Condition: Gout
Intervention: Biological: pegloticase
5 Completed
Has Results
Does Allopurinol Prolong a Treated, Acute Gout Flare?
Condition: Gout
Interventions: Drug: allopurinol;   Drug: Placebo (sugar pill)
6 Completed Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
Condition: Gout
Interventions: Drug: Placebo;   Drug: Allopurinol;   Drug: BCX4208
7 Completed
Has Results
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol;   Drug: Placebo
8 Completed Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life
Condition: Gout
Intervention:
9 Completed Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Condition: Gout
Intervention:
10 Completed Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
Condition: Gout
Interventions: Drug: placebo;   Drug: BCX4208
11 Terminated
Has Results
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
Condition: Gout
Interventions: Drug: PF-06743649;   Other: Placebo
12 Completed A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Condition: Gout
Intervention: Drug: Puricase
13 Completed Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Condition: Gout
Intervention: Drug: Canakinumab
14 Completed
Has Results
Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy
Condition: Gout
Interventions: Drug: Canakinumab 25 mg;   Drug: Canakinumab 50 mg;   Drug: Canakinumab 100 mg;   Drug: Canakinumab 200 mg;   Drug: Canakinumab 300 mg;   Drug: Canakinumab repeated every 4 week (q4wk);   Drug: Colchicine;   Drug: Allopurinol;   Drug: Placebo Matching Canakinumab;   Drug: Placebo Matching Colchicine
15 Completed
Has Results
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Condition: Gout
Intervention: Biological: Pegloticase
16 Completed
Has Results
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol
17 Completed Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
Conditions: Gout;   Gout Acute
Interventions: Drug: Allopurinol;   Drug: Placebo
18 Active, not recruiting Virtual Gout Clinic
Condition: Gout
Intervention: Behavioral: Pharmacist-Led Intervention
19 Completed Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Condition: Gout
Interventions: Biological: Rilonacept;   Other: Placebo
20 Completed PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Condition: Gout
Interventions: Drug: placebo;   Drug: rilonacept

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.